CNS Pharmaceuticals Inc. CNSP Archives

MondayJun 08, 2026 1:15 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Highlights Oversubscribed $22.5 Million Financing and Growth Strategy in Investor Presentation

CNS Pharmaceuticals (NASDAQ: CNSP) announced its participation in a virtual investor segment featuring Chief Financial Officer Steve O'Loughlin, who discussed the company's recently completed oversubscribed $22.5 million financing. The presentation focused on the factors supporting the successful capital raise following CNS Pharmaceuticals' strategic reset and acquisition-focused transformation. Management also addressed investor reception to the company's evolving strategy, the participation of healthcare-focused institutional investors and how the strengthened balance sheet positions CNS Pharmaceuticals to pursue potential transformational opportunities. The discussion highlighted the company's long-term growth strategy and efforts to create shareholder value as it advances its next phase of development. To…

ThursdayMay 14, 2026 9:50 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports First-Quarter 2026 Results, Advances Strategic Transformation

CNS Pharmaceuticals (NASDAQ: CNSP) reported first-quarter 2026 financial results while outlining progress in its strategic transformation toward an acquisition-driven growth model focused on clinical-stage neurology and oncology assets. Following quarter end, the company strengthened its balance sheet with a $22.5 million private placement, which, together with existing cash, is expected to support operations beyond 12 months as CNS pursues asset acquisitions and explores out-licensing opportunities for its legacy glioblastoma programs. To view the full press release, visit https://ibn.fm/HP5Xy About CNS Pharmaceuticals, Inc. CNS Pharmaceuticals is a biotechnology company focused on developing innovative therapies for serious diseases. With an experienced executive…

MondayMay 04, 2026 10:55 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Secures $22.5 Million Private Placement Financing

CNS Pharmaceuticals (NASDAQ: CNSP) announced it has entered into securities purchase agreements for a private placement expected to generate approximately $22.5 million in gross proceeds, with participation from institutional healthcare investors including ADAR1 Capital, Ikarian Capital, Stonepine Capital Management and Nazare Partners. The company said proceeds will support its strategy to acquire and advance new assets, along with working capital and general corporate purposes, while A.G.P./Alliance Global Partners acted as the sole placement agent for the transaction. To view the full press release, visit https://ibn.fm/usrIh About CNS Pharmaceuticals, Inc. CNS Pharmaceuticals is a biotechnology company focused on developing innovative therapies…

WednesdayMar 11, 2026 9:30 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Launches New Growth Strategy Focused On Neurology And Oncology Pipeline Expansion

CNS Pharmaceuticals (NASDAQ: CNSP) announced a new corporate growth strategy aimed at building a high-value pipeline in neurology and oncology through the acquisition or in-licensing of preclinical and clinical-stage therapeutic assets. Following a comprehensive strategic review incorporating clinical probability-of-success modeling, regulatory pathway analysis and market assessments, the company said it will prioritize programs with differentiated mechanisms, clear development pathways and strong commercial potential, while preparing legacy assets TPI 287 and berubicin for potential out-licensing to focus resources on advancing a new acquisition-driven pipeline. To view the full press release, visit https://ibn.fm/MutVR About CNS Pharmaceuticals, Inc. CNS Pharmaceuticals is a clinical-stage…

MondayMar 02, 2026 9:45 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Appoints Lynne Kelley as Chief Medical Officer

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company focused on developing novel treatments for primary and metastatic cancers of the brain and central nervous system, announced the appointment of Lynne Kelley, MD, FACS, as Chief Medical Officer. Dr. Kelley brings more than 20 years of global leadership experience spanning clinical development, translational medicine and regulatory strategy across oncology, rare diseases, CNS and medical devices, having led Phase 1–3 programs and supported regulatory approvals in the United States, Europe, China and Japan. She has previously served as chief medical officer at several biotechnology and medical device companies, including TISSIUM, Servier Pharmaceuticals, X4…

TuesdayFeb 17, 2026 10:15 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Appoints New Executive Leadership Team

CNS Pharmaceuticals (NASDAQ: CNSP) announced that recently appointed President and CEO Rami Levin, in alignment with the board, has recruited Steven O’Loughlin as chief financial officer, Eric Faulkner as chief technology officer and Dylan Wenke as chief business officer, effective March 2, 2026. The company said the appointments support its strategic evolution following a comprehensive review of its pipeline and capital allocation priorities, positioning CNS Pharmaceuticals to advance development programs with a focus on disciplined growth, operational execution and long-term value creation in treatments for brain and central nervous system cancers. To view the full press release, visit https://ibn.fm/lcSDZ About…

TuesdayJan 27, 2026 10:10 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Issues Shareholder Letter Outlining Strategic Review and Focus on TPI 287

CNS Pharmaceuticals (NASDAQ: CNSP) released a Letter to Shareholders from newly appointed President and Chief Executive Officer Rami Levin outlining a comprehensive strategic evaluation of the Company’s pipeline, operations and capital allocation priorities. The letter emphasizes a disciplined, patient-first approach centered on optimizing TPI 287 as the Company’s lead asset, refining its development and regulatory pathway, prioritizing high-value indications, and aligning resources toward milestone-driven execution, while also selectively evaluating pipeline expansion opportunities to support long-term shareholder value creation. To view the full press release, visit https://ibn.fm/bVf0V About CNS Pharmaceuticals, Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline…

FridayNov 14, 2025 9:45 am

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Targets Glioblastoma with Innovative Therapies, Addressing One of Oncology’s Greatest Unmet Needs

Glioblastoma multiforme (“GBM”) is an aggressive brain cancer with limited treatment options, and CEO John Climaco emphasized the company’s commitment to overcoming the blood-brain barrier, a key obstacle in brain cancer therapy. Lead candidate TPI 287, an abeotaxane, has shown early evidence of appearing to cross the blood-brain barrier and producing clinical responses. Phase 2 planning is underway following encouraging data from a Phase 1 combination study with bevacizumab (Avastin). The company’s repurposed global clinical network and regulatory progress position it for potential late-stage development in 2026. TPI 287 holds multiple Orphan Drug Designations, covering gliomas, neuroblastoma, and other CNS-related…

FridayAug 15, 2025 10:35 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Q2 2025 Results, Advances TPI 287 Toward Phase 2 GBM Trial

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company developing treatments for cancers in the brain and central nervous system, reported a Q2 2025 net loss of $2.4 million, slightly improved from $2.5 million in Q2 2024, driven by reduced Berubicin trial costs. R&D expenses rose to $1.2 million from $1.1 million on preparation for a TPI 287 trial, while G&A fell to $1.2 million from $1.4 million on lower legal, travel and stock-based compensation costs. The Company ended the quarter with $12.1 million in cash, sufficient to fund operations into the second half of 2026. CEO John Climaco said CNS is…

ThursdayAug 14, 2025 11:00 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at Webull Financial Biotech/MedTech Webinar Series

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharma company developing novel treatments for primary and metastatic cancers in the brain and central nervous system, announced it will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech, taking place virtually Aug. 19–21, 2025. To view the full press release, visit https://ibn.fm/JKPUq About CNS Pharmaceuticals, Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's drug candidate TPI 287 is an abeotaxane, which stabilizes microtubules and inhibits cell division, causing apoptosis…

Site Search

Company Search

Tag: CNS Pharmaceuticals Inc. CNSP